Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease

Journal of Cardiology

Volumn 57, Issue 1, 2011, Pages 115-122

  Lee, Chyan Jang ^a   Fan, Xin ^a   Guo, XiaoXin ^a   Medin, Jeffrey A ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiac directed therapy; Lentiviral vectors; Lysosomal storage disorders; Neonatal therapy

Indexed keywords

ALPHA GALACTOSIDASE; LENTIVIRUS VECTOR; LUCIFERASE; MYOSIN HEAVY CHAIN ALPHA; MYOSIN LIGHT CHAIN; TROPONIN T;

ARTICLE; FABRY DISEASE; GENE EXPRESSION; GENE TRANSFER; PROMOTER REGION; TRANSGENE; VIRAL GENE THERAPY;

ALPHA-GALACTOSIDASE; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FABRY DISEASE; GENE THERAPY; GENETIC VECTORS; HEART DISEASES; LENTIVIRUS; MICE; MICE, INBRED BALB C; MYOCARDIUM; PROMOTER REGIONS, GENETIC; TRANSGENES; TRIHEXOSYLCERAMIDES;

EID: 78650576176     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.08.003     Document Type: Article

References (35)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967, 276:1163-1167.
2. Vedder A.C., Strijland A., vd Bergh Weerman M.A., Florquin S., Aerts J.M., Hollak C.E. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 2006, 29:106-111.
3. Clarke J.T. Narrative review: Fabry disease. Ann Intern Med 2007, 146:425-433.
4. Linhart A., Elliott P.M. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007, 93:528-535.
5. Zarate Y.A., Hopkin R.J. Fabry's disease. Lancet 2008, 372:1427-1435.
6. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., Yoshida A., Kuriyama M., Hayashibe H., Sakuraba H., Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995, 333:288-293.
7. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001, 68:711-722.
8. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001, 345:9-16.
9. Hughes D.A., Elliott P.M., Shah J., Zuckerman J., Coghlan G., Brookes J., Mehta A.B. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008, 94:153-158.
10. Linthorst G.E., Hollak C.E., Donker-Koopman W.E., Strijland A., Aerts J.M. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004, 66:1589-1595.
11. Benichou B., Goyal S., Sung C., Norfleet A.M., O'Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 2009, 96:4-12.
12. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., Desnick R.J., Germain D.P. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004, 75:65-74.
13. Siatskas C., Medin J.A. Gene therapy for Fabry disease. J Inherit Metab Dis 2001, 24(Suppl. 2):25-41. [discussion 11-2].
14. Yoshimitsu M., Sato T., Tao K., Walia J.S., Rasaiah V.I., Sleep G.T., Murray G.J., Poeppl A.G., Underwood J., West L., Brady R.O., Medin J.A. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 2004, 101:16909-16914.
15. Yoshimitsu M., Higuchi K., Ramsubir S., Nonaka T., Rasaiah V.I., Siatskas C., Liang S.B., Murray G.J., Brady R.O., Medin J.A. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 2007, 14:256-265.
16. Yoshimitsu M., Higuchi K., Dawood F., Rasaiah V.I., Ayach B., Chen M., Liu P., Medin J.A. Correction of cardiac abnormalities in Fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J 2006, 70:1503-1508.
17. Gollan T.J., Green M.R. Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. J Virol 2002, 76:3558-3563.
18. Fielding A.K., Chapel-Fernandes S., Chadwick M.P., Bullough F.J., Cosset F.L., Russell S.J. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 2000, 11:817-826.
19. Gennari F., Lopes L., Verhoeyen E., Marasco W., Collins M.K. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther 2009, 20:554-562.
20. Frecha C., Costa C., Levy C., Negre D., Russell S.J., Maisner A., Salles G., Peng K.W., Cosset F.L., Verhoeyen E. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 2009, 114:3173-3180.
21. Kobinger G.P., Weiner D.J., Yu Q.C., Wilson J.M. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001, 19:225-230.
22. Amendola M., Venneri M.A., Biffi A., Vigna E., Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005, 23:108-116.
23. Gulick J., Subramaniam A., Neumann J., Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 1991, 266:9180-9185.
24. Su H., Joho S., Huang Y., Barcena A., Arakawa-Hoyt J., Grossman W., Kan Y.W. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci USA 2004, 101:16280-16285.
25. Wang G., Yeh H.I., Lin J.J. Characterization of cis-regulating elements and trans-activating factors of the rat cardiac troponin T gene. J Biol Chem 1994, 269:30595-30603.
26. Sato T., Ramsubir S., Higuchi K., Yanagisawa T., Medin J.A. Vascular endothelial growth factor broadens lentivector distribution in the heart after neonatal injection. J Cardiol 2009, 54:245-254.
27. Takahashi T., Kawai T., Ushikoshi H., Nagano S., Oshika H., Inoue M., Kunisada T., Takemura G., Fujiwara H., Kosai K. Identification and isolation of embryonic stem cell-derived target cells by adenoviral conditional targeting. Mol Ther 2006, 14:673-683.
28. Gruh I., Wunderlich S., Winkler M., Schwanke K., Heinke J., Blomer U., Ruhparwar A., Rohde B., Li R.K., Haverich A., Martin U. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene Med 2008, 10:21-32.
29. Subramaniam A., Jones W.K., Gulick J., Wert S., Neumann J., Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 1991, 266:24613-24620.
30. Lee K.J., Hickey R., Zhu H., Chien K.R. Positive regulatory elements (HF-1a and HF-1b) and a novel negative regulatory element (HF-3) mediate ventricular muscle-specific expression of myosin light-chain 2-luciferase fusion genes in transgenic mice. Mol Cell Biol 1994, 14:1220-1229.
31. Laumen H., Brunner C., Greiner A., Wirth T. Myosin light chain 1 atrial isoform (MLC1A) is expressed in pre-B cells under control of the BOB.1/OBF.1 coactivator. Nucleic Acids Res 2004, 32:1577-1583.
32. Harlan S.M., Reiter R.S., Sigmund C.D., Lin J.L., Lin J.J. Requirement of TCTG(G/C) direct repeats and overlapping GATA site for maintaining the cardiac-specific expression of cardiac troponin T in developing and adult mice. Anat Rec (Hoboken) 2008, 291:1574-1586.
33. Liu B.H., Wang X., Ma Y.X., Wang S. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther 2004, 11:52-60.
34. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
35. Bates D.O., Harper S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002, 39:225-237.